SAN DIEGO, Calif., January 8, 2026 – Bloom Science, Inc., a clinical-stage biotechnology company developing next-generation live biotherapeutic medicines targeting the gut-brain axis, today announced that members of its executive leadership team will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco and the upcoming 9th Annual Sachs Neuroscience Innovation Forum.
Bloom’s leadership team will meet with investors, strategic partners, and industry leaders during J.P. Morgan Healthcare Conference week, and will engage with neuroscience-focused investors and innovators at the Sachs Neuroscience Innovation Forum, which convenes global stakeholders advancing therapies for neurological and neurodegenerative disorders.
At these meetings, Bloom intends to highlight recent clinical progress from its lead program, BL-001, an orally delivered live biotherapeutic product designed to replicate key mechanisms of ketogenic biology. Phase 1 data demonstrated statistically significant placebo-adjusted weight loss and durable metabolic effects, supporting the program’s advancement toward Phase 2 development in obesity and rare epilepsies, including Dravet syndrome.
“Healthcare Conference week provides an important opportunity to engage both the broader investment community and specialized neuroscience investors,” said Christopher Reyes, PhD, Chief Executive Officer of Bloom Science. “We look forward to discussing our differentiated gut-brain axis approach and our plans to advance BL-001 into its next stage of clinical development.”
The Sachs Neuroscience Innovation Forum brings together leading companies, investors, and academic experts focused on advancing therapies across neurological diseases, including epilepsy, neurodegeneration, and psychiatric disorders. Bloom’s participation reflects its commitment to addressing complex metabolic and neurological conditions through a novel live biotherapeutic modality.
Bloom management will be available for scheduled one-on-one meetings during both conferences.
About Bloom Science
Bloom Science is a clinical-stage biotechnology company developing live biotherapeutic medicines targeting the gut-brain axis. Powered by its proprietary IrisRx™ discovery platform, Bloom designs therapeutics that modulate metabolic and neurological pathways to address complex diseases including obesity and rare epilepsies. Bloom is headquartered in San Diego, California.